Skip to main content

News

Media Release

2018

1.10.2018
Net asset value per HBM-share increases by 15.3 percent in the first half of the financial year to CHF 184.86 as at 30 September 2018

HBM Healthcare Investments’ net asset value per share (NAV) increased by 15.3% to CHF 184.86 in the first six months of the current financial year 2018/2019. The share price rose by 28.8% to CHF 178.40.

 

Based on the reported NAV, HBM Healthcare Investments expects a profit of around CHF 176 million for the first six months of the financial year. This compares to a profit of CHF 13.6 million for the same period of the previous year.

 

These results are preliminary based on the current state of work in preparing the financial statements. The semi-annual report September 2018 will be published on 25 October 2018.

 


Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

24.9.2018
Successful IPO of Y-mAbs Therapeutics increases net asset value per HBM-share by CHF 4.82 (+2.7%)

With Y-mAbs Therapeutics (Nasdaq: YMAB), another privately held portfolio company of HBM Healthcare Investments went public on Friday last week. The company issued 6 million new shares at a price of USD 16.00 per share, raising a total of USD 96 million. Y-mAbs’ share price rose to USD 24.00 (+50%) on the first trading day.


HBM Healthcare Investments invested USD 23.2 million in Y-mAbs in October 2017 and increased the position by a further USD 9.4 million in the IPO. Following the IPO, HBM Healthcare Investments owns 3.1 million shares worth USD 73.8 million, representing an ownership of approximately 9% in the company. The value increase of USD 41.1 million on the Y-mAbs investment raises the net asset value per HBM-share (NAV) by CHF 4.82 (+2.7%).


Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates, naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively.

 


Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

17.9.2018
Successful IPO of Principia Biopharma

Principia Biopharma (Nasdaq: PRNB), a so far privately held company in the portfolio of HBM Healthcare Investments, successfully completed its planned IPO on Friday last week. The company issued 6.25 million new shares at the upper end of the price range at USD 17.00 per share, raising a total of USD 106.25 million for the company. On the first trading day on Friday, the stock price rose to USD 32.65 (+92%).

 

HBM Healthcare Investments invested first USD 12 million in Principia in a private financing round prior to the IPO in August 2018 and increased its stake by an additional USD 7.2 million in the IPO. Following the IPO, HBM Healthcare Investments holds approximately 1.26 million shares worth USD 41.1 million. As a result of the IPO, the net asset value per HBM-share (NAV) increases by CHF 2.58 (+1.5%).

 

Headquartered in South San Francisco, California (USA), Principia Biopharma is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

 

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

11.9.2018
Registration of capital reductions in the commercial register completed

The reduction of the share capital by means of cancellation of 80’000 registered shares and the par value reduction of CHF 1.50 per share, which were both approved at the Annual Shareholders’ Meeting on 25 June 2018, have been registered in the commercial register.

 

The share capital of HBM Healthcare Investments Ltd now amounts to CHF 396’720’000.-, divided into 6'960'000 registered shares with a par value of CHF 57.00 each.  The par value repayment of CHF 1.50 to Shareholders will be made on 21 September 2018 (ex-date 19 September 2018).

 

 

Contact

For further information, please contact Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

5.9.2018
HBM Healthcare Investments takes USD 15 million stake in China’s Leading Online Pharmacy and Healthcare Services Platform Jianke

Jianke, a privately held company based in Guangzhou, China, today announced the closing of a USD 130 million financing round. HBM Healthcare Investments participated with USD 15 million in this financing.

 

Jianke was founded in 2006 and is the largest online B2C pharmacy and healthcare services platform in China. The company has served more than 100 million customers in China by offering 680’000 stock keeping units (SKUs) and its healthcare advisory services.

 

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.

25.7.2018
HBM Healthcare Investments Quarterly Report June 2018

HBM Healthcare Investments got off to a strong start in the first quarter of the 2018/2019 financial year, generating a profit of CHF 66.6 million for the first three months to 30 June 2018. Net asset value (NAV) per share rose by 5.8 percent to CHF 170.50, while the share price advanced by 13 percent to CHF 157.20.

 

The portfolio remains well diversified and balanced. Thanks to a number of new investments in private companies, this allocation now accounts for 39 percent of net assets, while the proportion of public portfolio companies has fallen slightly to 57 percent (corresponding to 45 percent when the market hedge is taken into account). Management remains confident about prospects for the future.

 

A number of acquisitions, initial public offerings and financial transactions on the part of portfolio companies contributed to this pleasing profit for the quarter: Eli Lilly took over the public immuno-oncology company ARMO BioSciences (profit contribution for the quarter under review: CHF 22.3 million) for USD 1.6 billion. Prior to and during the IPO, HBM Healthcare Investments invested a total of USD 22 million in ARMO. This investment generated a total profit of USD 57 million.

 

The quarter also saw AveXis, which operates in the gene therapy field, acquired by Novartis (profit contribution for the quarter under review: CHF 8.5 million). HBM Healthcare Investments had invested a total of USD 14 million in the public company since 2016 and realised an aggregate profit of USD 17 million from its holding.

 

Meanwhile, private company Aptinyx completed a successful IPO (profit contribution for the quarter under review: CHF 13.8 million). HBM Healthcare Investments took an initial USD 6.5 million stake in Aptinyx in December 2017 and increased its holding by a further USD 2 million as part of the IPO.

 

The takeover of private company TandemLife (Cardiac Assist) by LivaNova was completed at the beginning of April. HBM Healthcare Investments received about CHF 24 million from the upfront payment.

 

In addition, the holding in private Indian company Sai Life Sciences performed very successfully (profit contribution for the quarter under review: CHF 10.6 million). A major US private equity investor acquired a significant stake from co-investors and will provide the company with further growth capital. HBM Healthcare Investments did not exercise its right to sell its stake and will instead participate in the financing for the company. The holding in Sai Life Sciences has therefore been revalued on the basis of the company’s value following this transaction.

 

The 3.8 percent appreciation in the US dollar against the Swiss franc also had a positive effect on results for the quarter.

 

 

New investments in private companies

A capital commitment of USD 10 million was made to C-Bridge Capital during the quarter under review. C-Bridge is a private equity investor which specialises in the Chinese healthcare sector. In partnership with C-Bridge, HBM Healthcare Investments has made an initial direct investment of USD 3 million in Everest Medicines. Everest is developing a platform to licence compounds from abroad and distribute them in the Chinese healthcare market.

 

Additionally, a further four new investments were made in private companies:

 

> The Irish company Sublimity Therapeutics will receive a total of EUR 8 million, the first tranche of which – EUR 3.5 million – has already been paid. The company is conducting clinical trials of an oral formulation for a compound to treat patients with ulcerative colitis, a chronic inflammation of the colon.

 

> USD 4 million went to Corvidia Therapeutics, a spin-off of AstraZeneca that is based near Boston. Corvidia has an antibody to treat patients with chronic kidney disease in phase II clinical development.

 

> An investment commitment totalling EUR 5 million was made to Belgian company iTeos Therapeutics. The first tranche of EUR 1.6 million has been paid to date. iTeos operates in the immuno-oncology field.

 

> USD 5 million was invested in holding company Cure Everlife. USD 3 million of the total has been paid to date. Based in Singapore, Everlife is building a distribution platform for medical devices in south-east Asia.

 

 

Asset allocation

The new investments increase the share of the portfolio accounted for by private companies (including funds and milestone payments) slightly to 39 percent of net assets. The takeover of ARMO BioSciences meant that the share of net assets accounted for by public companies fell to 57 percent. About a fifth of this share remains hedged, further reducing the general market risk attached to public companies to 45 percent of net assets.

 

The portfolio thus displays a healthy balance between private and public companies with significant value-creation potential. In addition, HBM Healthcare Investments has sufficient liquidity to make new investments in private companies and to seize opportunities that arise in the public segment.

 

 

Outlook

Prospects remain largely unchanged. HBM Healthcare Investments expects the portfolio of private companies to generate further value over the next 18 months thanks to IPOs, trade sales and financing rounds. Further attractive new investments in private companies will also be finalised in the near future.

 

A number of potentially value-generating events – such as clinical study data and approval decisions – are expected for the portfolio of public companies. HBM Healthcare Investments expects these to have a positive overall effect on the Company’s net asset value.

 

All in all, the portfolio is well positioned in the current market climate in terms of both its mix between private and public companies, and its geographical allocation in the USA, Europe and Asia. 

 

The Quarterly Report June 2018 is available on the Company’s website https://www.hbmhealthcare.com/en/investors/financial-reports

 

 

Contact

For further information, please contact Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

.

 

25.6.2018
Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors

At today’s ordinary Shareholder’s Meeting of HBM Healthcare Investments Ltd the Shareholders approved all proposals submitted by the Board of Directors. A total of about 44% of all shares were represented at the Shareholders’ Meeting.

The Chairman of the Board of Directors, the Members of the Board of Directors as well as the Members of the Compensation Committee were all re-elected for a further term of one year. The Shareholders also approved the proposed compensation to the Board of Directors and to the Management.

 

Along with the reduction of the share capital by means of cancellation of 80’000 registered shares, the Shareholders also approved a withholding tax-exempt distribution from the reserve from capital brought in of CHF 5.50 per share. The cash payment to Shareholders will be made on 29 June 2018. Until 26 June 2018, the shares will be traded with entitlement for the cash distribution (as from 27 June 2018 without such entitlement, ex-date).

 

Further, the Shareholders approved an additional withholding tax-exempt cash distribution of CHF 1.50 per share by means of a par value reduction. The cash payment to Shareholders will be made after the expiration of the legal deadlines, presumably on 21 September 2018 (ex-date 19 September 2018).

 

After the entry of the two capital reductions in the commercial register, which is expected in early September 2018, the new share capital of HBM Healthcare Investments Ltd is CHF 396’720’000.-- and is divided in 6'960'000 registered shares with a par value of CHF 57.-- each.

 

The presentation shown at the Shareholders’ Meeting is available on the Company’s website http://hbmhealthcare.com/en/investors/information

 

 

Contact

For further information, please contact Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

22.6.2018
High demand by investors for the IPO of the HBM-portfolio company Aptinyx

The initial public offering (IPO) of Aptinyx (Nasdaq: APTX), a company in the portfolio of HBM Healthcare Investments, attracted considerable interest. The company increased its offering from 5.3 million shares to 6.4 million shares. The new shares were placed at a price of USD 16.00 per share, at the high end of the price range, which raised a total of USD 102 million in new capital for the company. On the first trading day, the share price rose to USD 20.20 (+26.3%).

 

HBM Healthcare Investments first invested USD 6.5 million in Aptinyx in December 2017 (purchase of 0.79 million shares at USD 8.22) and increased its stake by an additional USD 2 million in the initial public offering. Following the IPO, HBM Healthcare Investments holds approximately 0.92 million shares worth USD 18.55 million. As a result of the IPO, the net asset value per HBM-share (NAV) increases by CHF 1.21 (+0.68%).

 

Aptinyx is developing novel small molecule therapeutics for neurological disorders.

 

 

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

19.6.2018
Invitation to the 17th Ordinary Shareholders' Meeting incl. amended agenda item 9

Zug, 18. May 2018

 

HBM Healthcare Investments Ltd

 

Bundesplatz 1, 6300 Zug

 

Invitation to the 17th Ordinary Shareholders' Meeting

 

Monday, 25 June 2018, 2:00 pm

 

Theater Casino Zug
Artherstrasse 2 - 4
6300 Zug

 

The admission office opens at 1:30 pm.

Agenda and motions of the Board of Directors:

1.     Statutory financial statements and group financial statements 2017/2018;
reports of the auditors

Motion:       Approval of statutory financial statements and group financial statements for the 2017/2018 business year

2.     Discharge from liability of the members of the Board of Directors and Management

Motion:     Discharge from liability of the members of the Board of Directors and of the                                     Management for the 2017/2018 business year

3.     Appropriation of results

Motions:

 3.1      Appropriation of disposable profit of CHF 136'370'716 as follows:

in CHF

2017/2018

profit for the year

profit carry forward

54'974'908

81'422'808

disposable profit

136'370'716

– allocation to the general legal reserve

0

– carry forward to the new account

136'370'716

   

3.2    Withholding tax-exempt cash distribution from the reserve from capital brought in of CHF 5.50 per entitled share*, i.e. a maximum of CHF 38.3 million

                    * All registered shares in HBM Healthcare Investments Ltd which are not held by the Company itself are entitled to receive a distribution. Changes in the Company's holdings may still change the number of entitled shares.

In view of the business result, the Board of Directors proposes first a cash distribution of CHF 5.50 per share, in the form of a withholding tax-exempt dividend from the reserve from capital brought in. Should the motion be passed, the cash payment of CHF 5.50 per registered share will be made on 29 June 2018. Registered shares which are entitled to receive the dividend will be traded for the last time on 26 June 2018. As of 27 June 2018 they will be traded without the distribution entitlement (ex date). An additional distribution is proposed in agenda item 9.2.

4.       Elections regarding the Board of Directors

 

4.1 Re-elections of the Chairman and of the Members of the Board of Directors

Motions:

a.   Re-election of Mr Hans Peter Hasler as Chairman of the Board of Directors to the close of the 2019 Ordinary Shareholders' Meeting

 

b.   Re-election of Prof. Dr h.c. mult. Heinz Riesenhuber as member of the Board of Directors to the close of the 2019 Ordinary Shareholders' Meeting

 

c.   Re-election of Dr Eduard Holdener as member of the Board of Directors to the close of the 2019 Ordinary Shareholders' Meeting

 

d.   Re-election of Mr Robert A. Ingram as member of the Board of Directors to the close of the 2019 Ordinary Shareholders' Meeting

 

e.   Re-election of Dr Rudolf Lanz as member of the Board of Directors to the close of the 2019 Ordinary Shareholders' Meeting

 

f.    Re-election of Mr Mario Germano Giuliani as member of the Board of Directors to the close of the 2019 Ordinary Shareholders' Meeting

Mr Hans Peter Hasler has been a member of the Board of Directors since 2009, and its Chairman since 2011. To date he also was a member of the Compensation Committee. He knows the biotech business, having spent eight years in leading positions at Biogen Idec and, previously, Wyeth. Mr Hasler is CEO of Vicarius Pharma, Chairman of the Board of Directors of MIAC AG (Medical Imaging Analysis Center, a not-for-profit organisation of the University Hospital of Basel), member of the Board of Directors of Dr. Reddy's Laboratories and Minverva Neurosciences.

Mr Prof. Dr Heinz Riesenhuber has been a member of the Board of Directors since 2001, and its Vice-Chairman since 2006. He has also been a member of the Audit Committee. He is a certified chemist and has 15 years' industry experience as the CEO of subsidiaries of Metallgeschaft AG. Prof. Riesenhuber was a member of the German Federal Parliament from 1976 until 2017 and served as Federal Minister of Research and Technology from 1982 to 1993. Prof. Riesenhuber is a member of the Investors Committee of Heidelberg Innovation BioScience Venture II, as well as Chairman of the advisory board of Rock Tech Lithium Inc..

Mr Dr Eduard Holdener has been a member of the Board of Directors since 2008. He is an onco-haematologist, and has 14 years' clinical experience in a hospital environment in Switzerland and the USA, as well as 22 years' experience in clinical research and development at Roche. In his last eight years at Roche, he was Head of Global Clinical Deve-lopment, as well as member of the Pharma Executive and the Corporate Executive Committee. Dr Holdener is Chairman of the Board of Directors and CEO of NovImmune SA.

Mr Robert Ingram has been a Member of the Board of Directors since 2006. He is also a member of the Nominating Committee and a member of the Compensation Committee. He is an economist with world-wide knowledge and personal network in the pharma industry, especially in the USA, where the majority of HBM Healthcare Investments' portfolio companies are based. Mr Ingram worked at GlaxoSmithKline for 20 years, in positions including Chairman, COO and CEO. He is Chairman of the Board of Directors of Novan Inc., Viamet Pharmaceuticals Inc., Cree Inc. and BioCryst Pharmaceuticals Inc..

Mr Dr Rudolf Lanz has been a member of the Board of Directors since 2003. He is also a member of the Audit Committee and a member of the Nominating Committee. He has a master's degree in economics and a doctorate in law, and has longstanding professional experience in acquisitions, divestments, mergers and major financing transactions. For 20 years, Dr Lanz worked mainly in management positions at Ernst & Young, before founding "The Corporate Finance Group" with partners, and becoming the Chairman of its Board of Directors.  Dr Lanz is a member of the Board of Directors of Pearls Fashion Holding AG and of MIAC AG (Medical Imaging Analysis Center, a not-for-profit organisation set up by the University Hospital of Basel).

Mr Mario Germano Giuliani has been a member of the Board of Directors since 2012. He is also a member of the Compensation Committee. He is an economist. In the course of 16 years at his family pharmaceutical company, Milan-based Giuliani SpA, he has held positions at all levels: member of the Board of Directors since 1999, Chairman of the Board of Directors from 2003-2014 and Chief Executive Officer from 2001-2014. Mr. Giuliani is also a member of the Investment Committee of Mosaix Ventures LLP and Royalty Pharma, member of the Board of Directors of Jukka LLC as well as Chairman of the Board of Directors of NGR (Monaco) SAM and Fair-Med Healthcare AG.

4.2  Re-election of the members of the Compensation Committee

Motions: 

a.   Re-election of Mr Mario Germano Giuliani as a member of the Compensation Committee to the close of the 2019 Ordinary Shareholders' Meeting

 

b.   Re-election of Mr Robert Ingram as a member of the Compensation Committee to the close of the 2019 Ordinary Shareholders' Meeting

To date Mr Hans Peter Hasler was a member of the Compensation Committee too. He now wishes to refrain from re-election to this committee. The Board of Directors sees no need for a replacement.

 

5.    Compensation to the Board of Directors and to the Management

5.1 Fixed compensation to the Board of Directors

Motion:   Approval of the maximum fixed compensation to the Board of Directors of CHF 450’000 (including social security contributions) for the time between the Ordinary Shareholders’ Meetings 2018 and 2019

5.2 Variable compensation to the Board of Directors

Motion:   Approval of the variable compensation to the Board of Directors of CHF 1'017'600, plus pro rata social security contributions of CHF 36'082, for the 2017/2018 business year

5.3 Fixed compensation to the Management

Motion:   Approval of the maximum fixed compensation to the Management of CHF 330‘000 (including social security contributions) for the time between 1 July 2018 and 30 June 2019

The amounts proposed are explained in detail in the Compensation Report. Due to the fact that the High Water Mark has been exceeded, the Members of the Board of Directors are entitled to a variable compensation for the financial year 2017/2018. There is currently no agreement for a variable compensation to the Management in place.

6.    Appointment of auditors

Motion:    Re-appointment of Ernst & Young AG, Zurich, as auditors of the statutory financial statements and the group financial statements for the 2018/2019 business year

7.    Appointment of independent proxy-holder

Motion:    Appointment of KBT Treuhand AG, Zurich, as independent proxy-holder to the close of the 2019 Ordinary Shareholders' Meeting

8.    Reduction of share capital by means of cancellation of own shares

Motion:   (1)   Reduction of share capital of CHF 411'840'000.-- to CHF 407'160'000.-- by cancellation of 80‘000 registered shares at a par value of CHF 58.50 each;

                 (2)   Formal acknowledgement of the audit report from Ernst & Young AG, which states that creditor receivables are covered in full even after the share capi-tal has been reduced;

                 (3)   Amendment of Art. 3 of the Articles of Association, concerning share capital, as follows (changes marked):

                        "The share capital of the corporation is CHF 411'840'000.-- 407'160'000.-- and is divided in 7'040'000 6‘960‘000 registered shares with a par value of CHF 58.50 each. All shares are fully paid in."

As part of the 2016 share buy-back programme, up to the date on which this invitation was sent out, the Company acquired another 80‘000 of its own shares, i.e. about 1.1% of the shares outstanding, via a second trading line on SIX Swiss Exchange AG, which are to be cancelled at the Ordinary Shareholders' Meeting.

9.    Nominal value reduction and partial repayment (additional distribution)

Motion:   (1)   Reduction of the share capital from CHF 407'160'000.-- [after execution of agenda item 8] to CHF 396'720'000.-- by reducing the par value of the 6'960'000 registered shares from CHF 58.50 to CHF 57.-- and repayment of CHF 1.50 per share to the shareholders;

                 (2)   Formal acknowledgement of the audit report of Ernst & Young AG, which states that creditor receivables are covered in full even after the share capital has been reduced;

 

                 (3)   Amendment of Art. 3 of the Articles of Association, concerning the share capital, as follows (changes marked, depending on agenda item 8):

"The share capital of the corporation is CHF 407,160,000.-- 396'720'000.-- and is divided in 6'960'000 registered shares with a par value of CHF 58.50 57.-- each. All shares are fully paid-in."

10.  Miscellaneous

 

Documentation

The 2017/2018 annual report, including the statutory financial statements, the group financial statements, the compensation report, as well as the reports of the auditors, is sent out to all shareholders entered in the Shareholders' Register unless they have requested not to receive a copy. It is also available for review at Bundesplatz 1, 6300 Zug, Monday to Friday from 9.00 am to 5.00 pm. It can be ordered from the same address. Please call +41 (0)41 710 75 77. The same applies to the Ernst & Young AG audit reports with regard to agenda items 8 and 9.1. The annual report is also available on the www.hbmhealthcare.com website.

Admission cards / voting materials

Shareholders who are entered in the Shareholders' Register with the right to vote as at 5.00 pm on 15 June 2018 (the qualifying date) will receive the invitation as well as, upon request, a personal admission card and the voting materials directly from the company.

Shareholders who are entitled to vote according to the Shareholders' Register as of the qualifying date may participate in the Ordinary Shareholders' Meeting. Each share carries one vote. Shareholders who have sold their shares before the Ordinary Shareholders' Meeting takes place are no longer entitled to vote.

Granting of powers of attorney

Shareholders who do not participate in person in the Ordinary Shareholders' Meeting may appoint as a representative a different shareholder, a third party, or Mr Reto Leemann, chartered fiduciary agent, KBT Treuhand AG, Zimmergasse 16, 8032 Zurich, as independent proxy holder in the sense of Art. 689c of the Swiss Code of Obligations. Granting of powers of attorney to members of governing bodies or custody accounts is illegitimate.

The power of attorney on the registration form must be filled in accordingly, signed and returned to the independent proxy holder, or to the Shareholders' Register at Computershare Switzerland Ltd., Baslerstrasse 90, CH-4600 Olten, by 20 June 2018 at the latest.

In the absence of any specific instructions, the independent proxy-holder will be deemed to have been instructed to exercise the voting right in favour of the motions of the Board of Directors. This also applies to motions put forward in the Ordinary Shareholders’ Meeting.

As an alternative to written power of attorneys, Shareholders have the opportunity to submit power of attorneys and voting instructions to the independent proxy-holder electronically via the platform https://ip.computershare.ch/hbmag of Computershare Switzerland Ltd. Shareholders who wish to make use of this may follow the enclosed instructions regarding the opening of a Shareholder account and the registration to the Ordinary Shareholders’ Meeting.

Admission office

The admission office opens at 1.30 pm on the day of the Ordinary Shareholders' Meeting. Shareholders are asked to present their admission cards at the entrance.

Registration

We ask you kindly to return the registration form by 20 June 2018 if you intend to participate in the Ordinary Shareholders' Meeting.

Reception

The Board of Directors is pleased to invite you to a reception after the meeting.

 

Zug, 1 June 2018                                               On behalf of the Board of Directors
The Chairman:                                                   Hans Peter Hasler

13.6.2018
Amended motion of the Board of Directors for agenda item 9

Due to the ongoing debate and last week’s decision by the Council of States in Switzerland on the tax bill 17, the Board of Directors of HBM Healthcare Investments AG has decided to amend agenda item 9 of the invitation for the Annual Shareholders Meeting taking place on 25 June 2018 as follows:
 

The two motions of the Board of Directors for a par value reduction of CHF 30.- per share to increase the reserve from capital brought in (agenda item 9.1) and the subsequent cash payment of CHF 1.50 per share from this increased reserve (agenda item 9.2) shall be limited to a simple reduction in par value with a cash payment of CHF 1.50 per share.
 

The proposed cash distribution for the 2017/2018 financial year thus remains unchanged at a total of CHF 7.00 per share. If approved, CHF 5.50 per share will be paid, free of withholding tax, from the existing capital reserve after the Annual General Meeting (payment date June 29, 2018, ex date June 27, 2018). A further CHF 1.50 per share will be paid after the statutory deadline as a withholding tax-exempt par value repayment, expected on September 21, 2018 (ex date September 19, 2018).
 

This amended resolution does not change the distribution policy of the company. It merely serves the purpose of optimally preserving the company's withholding tax-free distributable substrate. This is due to the development in the ongoing debate on the tax bill 17 concerning the introduction of a possible repayment rule for distributions from the capital reserve and the legal uncertainty currently associated with it.
 

Shareholders will receive the voting documents for the amended motion under agenda item 9 by post this week.

Contact

For further information, please contact Erwin Troxler on +41 41 710 75 77, or at erwin.troxler@hbmhealthcare.com

13.6.2018
Amendment to agenda item 9 in the invitation to the 17th Ordinary Shareholders’ Meeting on 25 June 2018

Due to the ongoing debate and last week’s decision by the Council of States in Switzerland on the tax bill 17, the Board of Directors of HBM Healthcare Investments AG has decided to amend agenda item 9 of the invitation for the Annual Shareholders Meeting taking place on 25 June 2018 as follows:
 

The two motions of the Board of Directors for a par value reduction of CHF 30.- per share to increase the reserve from capital brought in (agenda item 9.1) and the subsequent cash payment of CHF 1.50 per share from this increased reserve (agenda item 9.2) shall be limited to a simple reduction in par value with a cash payment of CHF 1.50 per share.
 

The proposed cash distribution for the 2017/2018 financial year thus remains unchanged at a total of CHF 7.00 per share. If approved, CHF 5.50 per share will be paid, free of withholding tax, from the existing capital reserve after the Annual General Meeting (payment date June 29, 2018, ex date June 27, 2018). A further CHF 1.50 per share will be paid after the statutory deadline as a withholding tax-exempt par value repayment, expected on September 21, 2018 (ex date September 19, 2018).
 

This amended resolution does not change the distribution policy of the company. It merely serves the purpose of optimally preserving the company's withholding tax-free distributable substrate. This is due to the development in the ongoing debate on the tax bill 17 concerning the introduction of a possible repayment rule for distributions from the capital reserve and the legal uncertainty currently associated with it.
 

Shareholders will receive the voting documents for the amended motion under agenda item 9 by post this week.

Contact

For further information, please contact Erwin Troxler on +41 41 710 75 77, or at erwin.troxler@hbmhealthcare.com

1.6.2018
Invitation to the 17th Ordinary Shareholders' Meeting
1.6.2018
Publication of Annual Report 2017/2018 and Invitation to the Ordinary Shareholders' Meeting
18.5.2018
HBM Healthcare Investments reports a profit of CHF 115.9 million for the 2017/2018 financial year; Portfolio will be enriched with further new investments; Positive outlook for the portfolio allows for a 20 percent increase of the proposed cash…
11.5.2018
Eli Lilly announces tender offer for HBM-Portfolio Company ARMO BioSciences for USD 1.6 billion
3.4.2018
HBM Healthcare Investments increases net asset value per share (NAV) by 11 percent in the 2017/2018 financial year; Net profit of around CHF 115 million expected; Share price rises by 34 percent
29.3.2018
Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million
15.2.2018
HBM Healthcare Investments portfolio company, TandemLife, to be acquired for up to USD 250 million in cash
29.1.2018
Successful IPO of HBM-Portfolio Company ARMO BioSciences
25.1.2018
A strong third quarter further extended HBM Healthcare Investments’ profit for the first nine months of the 2017/2018 financial year to a total of CHF 85.6 million
3.1.2018
Delightful 2017 for HBM Healthcare Investments with 26% value increase of the NAV and 40% gain on the share price

2017

5.12.2017
CSL and HBM-Portfolio Company Vitaeris Announce Strategic Partnership with Option to Acquire
30.10.2017
Novartis announces tender offer for HBM-Portfolio Company Advanced Accelerator Applications for USD 3.9 billion
25.10.2017
HBM Healthcare Investment Half-Year Report September 2017
24.10.2017
Y-mAbs Therapeutics closes USD 50 million financing round led by HBM Healthcare Investments
6.10.2017
HBM Healthcare Investments announces investment of USD 30 million in Harmony Biosciences
2.10.2017
NAV Key Figures as at 30 September 2017
14.9.2017
Capital reduction completed
25.7.2017
HBM Healthcare Investments Quarterly Report June 2017
30.6.2017
NAV Key Figures as at 30 June 2017
26.6.2017
Shareholders’ Meeting approved all proposals by the Board of Directors
2.6.2017
Publication of Annual Report 2016/2017 and Invitation to the Ordinary Shareholders’ Meeting
2.6.2017
Invitation to the 16th ordinary Shareholders’ meeting
23.5.2017
Bioverativ acquires HBM-portfolio company True North Therapeutics for up to USD 825 million plus assumed cash
16.5.2017
HBM Healthcare Investments generated a profit of CHF 136.8 million for the 2016/2017 financial year and increased net asset value per share by 15.2 percent. Board of Directors proposing an increase in the cash dividend of 30 centimes, to…
27.4.2017
HBM Healthcare Investments commits EUR 20 million in growth capital to Switzerland based Amicus SA
3.4.2017
HBM Healthcare Investments expects to report a net profit of around CHF 136 million for the financial year 2016/2017 – increase of the net asset value per share of around 15 percent
31.1.2017
HBM Healthcare Investments Quarterly Report 2016
27.1.2017
Two IPOs from the HBM Healthcare Investments portfolio increase net asset value per HBM-share by CHF 2.30
3.1.2017
Net Asset Value per HBM-share of CHF 133.43 as at 31 December 2016

2016

28.10.2016
HBM Healthcare Investments Quarterly Report September
18.10.2016
HBM Healthcare Investments invests USD 10 million in True North Therapeutics
4.10.2016
Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung
4.10.2016
Rachat d’actions propres dans le but d’une réduction de capital (103 KB)
4.10.2016
HBM Healthcare Investments launches a new share buy-back programme
3.10.2016
Net asset value (NAV) of CHF 139.42 as at 30 September 2016
30.9.2016
HBM Healthcare Investments terminates share buy-back programme 2014
7.9.2016
Capital reduction completed
29.7.2016
HBM Healthcare Investments Quarterly Report June 2016
24.6.2016
Shareholders’ Meeting approved all proposals by the Board of Directors
17.6.2016
Paratek Pharmaceuticals Announces Positive Phase 3 Results for its Antibiotic Omadacyline
10.6.2016
Recommended all share merger of Skyepharma and Vectura becomes effective
30.5.2016
Annual Report 2015/2016
30.5.2016
Invitation to the 15th Ordinary Shareholders’ Meeting
30.5.2016
Publication of Annual Report 2015/2016 and Invitation to the Ordinary Shareholders’ Meeting
18.5.2016
HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite a negative market environment. Unchanged cash dividend of CHF 5.50 per share.
1.4.2016
HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite pronounced market correction in healthcare sector
16.3.2016
Skyepharma to merge with Vectura Group
15.2.2016
Closing of the sale of Ellipse Technologies to NuVasive
10.2.2016
HBM Healthcare Investments adds cancer immunotherapy company ARMO BioSciences to portfolio
29.1.2016
HBM Healthcare Investments Quarterly Report December 2015
12.1.2016
HBM Healthcare Investments backs Iconic Therapeutics to advance development of a novel, disease modifying approach in retinal diseases
6.1.2016
Sale of Ellipse Technologies to NuVasive for an upfront consideration of USD 380 million and a potential additional milestone payment of USD 30 million in cash boosts net asset value per HBM-share by CHF 9.70 (+6.5%)
4.1.2016
Strong increase of net assets by CHF 208 million in the quarter leads to a new high of the NAV per HBM-share of CHF 149.76 as at 31 December 2015

2015

15.12.2015
Cathay Industrial Biotech to set foundation for further successful corporate development with financing of USD 135 million
23.11.2015
HBM Healthcare Investments participates in CHF 60 million financing of Swiss women’s health company ObsEva
19.11.2015
HBM Healthcare Investments commits to invest USD 10 Million in clinical-stage company Eiger BioPharmaceuticals
12.11.2015
Initial Public Offering of Advanced Accelerator Applications boosts Net Asset Value per HBM share by CHF 5.20 (+4.2%)
30.10.2015
HBM Healthcare Investments Quarterly Report September 2015
1.10.2015
Net asset value (NAV) of CHF 121.12 as at 30 September 2015
28.9.2015
Advanced Accelerator Applications: Detailed Phase 3 Study Results Presented at the European Cancer Congress 2015 Demonstrate that Lutathera® Significantly Improves Progression-Free Survival in Patients with Advanced Midgut Neuroendocrine…
28.9.2015
Advanced Accelarator Applications Results from pivotal Phase 3 NETTER-1 Study
21.9.2015
Initial Public Offering of Nabriva Therapeutics
16.9.2015
Advanced Accelerator Applications’ (AAA) Pivotal Phase 3 NETTER-1 Study of Lutathera® Met Primary Endpoint - Data will be Presented at the European Cancer Congress 2015
15.9.2015
Capital reduction completed
21.8.2015
Raptor Pharmaceuticals Acquires Rights to QuinsairTM
31.7.2015
HBM Healthcare Investments Quarterly Report June 2015
2.7.2015
HBM Healthcare Investments AG has closed the books early and has fixed the issue amount of the combined bond tranches at CHF 100 million
1.7.2015
HBM Healthcare Investments NAV Key Figures as at 30.6.2015
30.6.2015
HBM Healthcare Investments announces the issue of two bond tranches, one with a 6 year and the other with a 8 year term with a minimum issue amount of CHF 50 million each
26.6.2015
Shareholders approved all proposals and recommendations by the Board of Directors
2.6.2015
Shareholders’ Letter June 2015
2.6.2015
Invitation to the 14th ordinary Shareholders’ Meeting on 26 June 2015
13.5.2015
HBM Healthcare Investments closed financial year 2014/2015 with a net profit of CHF 257.5 million - Proposed cash dividend of CHF 5.50 per share
1.4.2015
Net asset value (NAV) per share of CHF 140.60 as at 31 March 2015
30.1.2015
HBM Healthcare Investments Quarterly Report December 2014
16.1.2015
NAV Key Figures as at 15 January 2015 / Comment on the impact of foreign exchange rates
5.1.2015
HBM Healthcare Investments reports substantial value growth in calendar year 2014

2014

3.11.2014
Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung
3.11.2014
Rachat d’actions propres destiné à réduire le capital-actions
3.11.2014
Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung
3.11.2014
Paratek Pharmaceuticals completes merger with Transcept Pharmaceuticals
31.10.2014
HBM Healthcare Investments launches share buy-back programme
28.10.2014
HBM Healthcare Investments takes USD 8 million stake in Vascular Dynamics
27.10.2014
Probiodrug accomplishes Initial Public Offering at Amsterdam’s Euronext
16.10.2014
Initial Public Offering of Forward Pharma increases Net Asset Value per share by CHF 2.32
1.10.2014
HBM Healthcare Investments NAV Key Figures as at 30 September 2014
25.7.2014
HBM Healthcare Investments Quarterly Report June 2014
2.7.2014
Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals
1.7.2014
HBM Healthcare Investments Key Figures as at 30 June 2014
20.6.2014
Shareholders approved all proposals and recommendations by the Board of Directors
17.6.2014
Result from share buy-back through the issue of put-options
27.5.2014
Shareholders´ letter
27.5.2014
Invitation to the 13th Ordinary Shareholders´ Meeting
27.5.2014
Media Release: Invitation to the Ordinary Shareholders´ Meeting
23.5.2014
PTC Therapeutics receives positive opinion from European Medical Agency for TranslarnaTM
22.5.2014
Buy-back of own registered shares for the purpose of capital reduction through the issuance of tradable put options
21.5.2014
HBM Healthcare Investments announces terms of share buy-back involving the issue of put options
20.5.2014
Ophthotech enters into licensing agreement with Novartis – share price rises more than 20% in after-market trading
19.5.2014
HBM Healthcare Investments publishes Annual Report 2013/2014
13.5.2014
HBM Healthcare Investments to end “share buy-back programme 2012”
12.5.2014
HBM Healthcare Investments shareholders participate in outstanding annual result: issue of put options to accelerate share buy-backs and proposal of a cash dividend of CHF 3.00 per share to the Ordinary Shareholders´ Meeting
1.4.2014
Net Asset Value per share of CHF 108.76 as at 31 March 2014
31.3.2014
Skyepharma announces £112 million capital increase and launches tender offer for outstanding bonds
17.2.2014
HBM Healthcare Investments participates with EUR 20 million in financing round of Advanced Accelerator Applications
31.1.2014
Quarterly Report December 2013
13.1.2014
Investment in Intercept with spectacular value increase of 647%
3.1.2014
HBM Healthcare Investments achieves compelling value increase of 65 percent in the calendar year 2013

2013

30.10.2013
HBM Healthcare Investments Quarterly Report September 2013
26.9.2013
Ophthotech IPO increases NAV by CHF 4.96 per share (+6.3%)
24.9.2013
Ophthotech increases price range for IPO to USD 19-20 per share
23.9.2013
Quarterly Report June 2013
23.9.2013
Information on Ophthotech IPO
1.7.2013
Key Figures (NAV, net assets, net result for the quarter) as as 30 June 2013
21.6.2013
Shareholders approved all proposals by the Board of Directors
21.6.2013
PTC Therapeutics completes initial public offering
29.5.2013
Ophthotech secures financing of USD 175 million for phase-III clinical trial of FovistaTM
28.5.2013
Annual Report 2012/2013 and invitation to the ordinary Shareholders’ Meeting
13.5.2013
Invitation to the ordinary Shareholders´ Meeting
2.5.2013
HBM Healthcare Investments achieves net profit of CHF 67 million for the year and proposes a par-value repayment of CHF 1.50 per share to shareholders´ meeting
2.4.2013
Key Figures (NAV, net assets, net result) as at 31.03.2013
21.3.2013
Successful IPO for Enanta Pharmaceuticals
30.1.2013
HBM Healthcare Investments Quarterly Report December 2012

2012

30.10.2012
HBM Healthcare Investments Quarterly Report September 2012
10.9.2012
Rachat d’actions propres destiné à réduire le capital-actions
3.9.2012
HBM Healthcare Investments starts new share buy-back programme
27.7.2012
HBM Healthcare Investments Quarterly Report June 2012
3.7.2012
SkyePharma receives approval for flutiform® in Europe
22.6.2012
Shareholders’ Meeting approved all proposals by the Board of Directors and Management presents confident outlook
13.6.2012
Ophthotech’s novel anti-PDGF combination agent FovistaTM demonstrated superior efficacy over Lucentis® monotherapy in large controlled wet AMD trial
12.6.2012
Basilea enters into global agreement with Stiefel, a GlaxoSmithKline company, for Toctino® (alitretinoin)
1.6.2012
Nabriva Therapeutics signs Agreement for Collaboration and Option for Sale of the Company
29.5.2012
Invitation to the ordinary Shareholders´ Meeting
29.5.2012
Annual Report 2011/2012 and invitation to the ordinary Shareholders´ Meeting
3.5.2012
HBM BioVentures publishes annual results for 2011/12
3.4.2012
HBM BioVentures publishes preliminary results for the fourth quarter and the full financial year 2011/12
22.2.2012
Enanta signs significant collaboration agreement with Novartis for Hepatitis C programme
10.2.2012
HBM Report Shows Strong M&A Activity in the Pharma Sector
9.2.2012
Successful Initial Public Offering of ChemoCentryx
27.1.2012
HBM BioVentures Quarterly Report as at 31 December 2011
27.1.2012
Promising new approach to the treatment of wet age-related macular degeneration
24.1.2012
ChemoCentryx announces details for its planned Initial Public Offering
24.1.2012
Vivacta sold to major pharmaceutical company for USD 90 million
6.1.2012
ChemoCentryx licenses investigational drug for rheumatoid arthritis to GlaxoSmithKline
6.1.2012
Pivotal clinical trial of Lux Biosciences misses endpoint

2011

30.11.2011
PTC Therapeutics signs licensing agreement with Roche for Spinal Muscular Atrophy (SMA) Programme (46 KB) 30.11.2011
31.10.2011
New CFO at HBM BioVentures
31.10.2011
Pacira Pharmaceuticals announces U.S. FDA approval of EXPAREL(TM) for postsurgical pain management
28.10.2011
HBM BioVentures Quarterly Report as at 30 September 2011
6.10.2011
Letter of HBM BioVentures to Basilea Pharmaceutica AG: Request to call an Extraordinary Shareholders Meeting
6.10.2011
Request to call an Extraordinary Shareholders Meeting of Basilea
31.8.2011
HBM BioVentures Investor Information
31.8.2011
Closing of the sale of mtm laboratories to Roche
26.8.2011
Press Release
7.8.2011
Cathay Industrial Biotech discontinues its IPO process
1.8.2011
Cathay Industrial Biotech announces further details for its IPO
26.7.2011
HBM BioVentures Quarterly Report as at 30 June 2011
20.7.2011
Cathay Industrial Biotech, third-largest portfolio position of HBM BioVentures, is planning an IPO
19.7.2011
HBM BioVentures sells mtm laboratories, the biggest private investment in the portfolio
24.6.2011
Shareholders´ meeting approved all proposals by the Board of Directors by a very large majority
31.5.2011
HBM bioVentures: Annual Report 2010/2011 and invitation to the ordinary shareholders´ meeting
31.5.2011
Invitation to the ordinary shareholders meeting
5.5.2011
HBM BioVentures closes the operationally successful financial year 2010/2011 with loss of CHF 56 million owing to the sharp rise of the Swiss franc
14.4.2011
Trade sale of Mpex Pharmaceuticals
1.4.2011
HBM BioVentures: Successful sale of indirect holding in China Health System generates cash inflow of approximately USD 27 million
11.3.2011
Closing of the sale of PharmaSwiss to Valeant
4.2.2011
Pacira Pharmaceuticals finances itself via IPO
1.2.2011
HBM BioVentures realises a profit of EUR 41.9 million through the sale of PharmaSwiss to Valeant
24.1.2011
HBM BioVentures Quarterly Report as at 31 Dezember 2010

2010

26.10.2010
HBM BioVentures Quarterly Report as at 30 September 2010
7.10.2010
HBM BioVentures sells its investment in Sloning
21.9.2010
Successful sale of Asthmatx, a company from HBM BioVentures´ portfolio, to Boston Scientific increases liquidity by CHF 4 million
27.7.2010
HBM BioVentures Quarterly Report as at 30 June 2010
13.7.2010
HBM BioVentures’ largest public investment – Micrus – acquired by Johnson & Johnson
2.7.2010
HBM BioVentures sells USD hedging position at a profit
25.6.2010
Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM…
16.6.2010
Interview with Dr Andreas Wicki, CEO of HBM BioVentures
2.6.2010
HBM BioVentures: Annual Report financial year 2009/2010 and invitation to its Shareholders´ meeting
2.6.2010
HBM BioVentures delegates the execution of the share buy-back programme delegated to Bank Sarasin/NZB to avoid interruptions
2.6.2010
HBM BioVentures: Invitation to the 9th Ordinary Shareholders´ Meeting
20.5.2010
HBM BioVentures hedges some of the currency risks
3.5.2010
HBM BioVentures closes successful 2009/2010 financial year with a profit of CHF 66 million
20.4.2010
HBM BioVentures is 96% equity-financed after redemption of the convertible bond
12.3.2010
HBM BioVentures Investor Information
10.2.2010
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMAv
29.1.2010
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
13.1.2010
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
4.1.2010
HBM BioVentures sells Ziemer Group investmen
4.1.2010
Major financing round for PTC Therapeutics at 2.2 times the previous valuation

2009

11.12.2009
Successful IPO for China Nuokang
9.12.2009
Financing round for Ophthotech
20.11.2009
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
30.10.2009
HBM BioVentures Quarterly Report as at 30 September 2009
8.10.2009
Paratek Pharmaceuticals, a portfolio company of HBM BioVentures, signs licence agreement over USD 485 million
2.10.2009
Closing of the successful sale of BRAHMS to Thermo Fisher Scientific
14.9.2009
Successful sale of ESBATech, a Swiss company from HBM BioVentures´ portfolio, to Alcon leads to immediate NAV increase of CHF 1.75 and cash inflow of CHF 18.6 million
4.9.2009
HBM BioVentures Ordinary Shareholders´ Meeting All Board of Directors´ proposals approved with clear majority
26.8.2009
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
11.8.2009
HBM BioVentures: Invitation to the 8th Ordinary Shareholders´ Meeting
11.8.2009
HBM BioVentures: Agenda for the Shareholders´ Meeting
30.7.2009
HBM BioVentures Quarterly Report as at 30 June 2009
8.7.2009
HBM BioVentures reduces its outstanding Going Public Convertible Bond by CHF 39 million
3.6.2009
HBM BioVentures Annual Report 2008/2009
11.5.2009
HBM BioVentures: letter to shareholders
2.4.2009
HBM BioVentures net asset value as at 31 March 2009
30.1.2009
HBM BioVentures quarterly report as at 31 December 2008

2008

21.11.2008
HBM BioVentures holds over 5% of its own shares
12.11.2008
Sale of private portfolio company Panomics
27.10.2008
HBM BioVentures quarterly report as at 30 September 2008 - stable net asset value (NAV)
9.10.2008
HBM BioVentures holds over 3% of its own shares
30.9.2008
Disclosure of shareholdings in accordance with Articles 9 and 17 of the Federal Act of Stock Exchanges and Securities Trading - SFBC
26.9.2008
Takeover of public portfolio company CryoCath Technologies
24.9.2008
Share buyback - listing advertisement English
24.9.2008
Share buyback - listing advertisement French
22.9.2008
HBM BioVentures launches share buyback programme and resolves to make par value repayments
30.7.2008
HBM BioVentures quarterly report as at 30 June 2008 - private portfolio boosts value
22.7.2008
Significant cooperation agreement for portfolio company PTC Therapeutics
30.6.2008
Annual General Meeting of HBM BioVentures Ltd - all Board of Directors proposals approved
30.6.2008
Capital management measures to boost share appeal
5.6.2008
Successful private portfolio positions reduce negative impact of difficult equity market climate in 2007/2008 financial year
20.5.2008
New financing for the porfolio company PharmaSwiss - positive impact on HBM BioVentures´ net asset value (NAV) of CHF 2.90 per share
2.5.2008
HBM BioVentures realises remaining gains on USD currency hedge positions
11.3.2008
HBM BioVentures realises gains on USD currency hedge positions (
6.2.2008
The first day of trading in HBM BioVentures shares on the SWX Swiss Exchange is 14 February 2008
28.1.2008
HBM BioVentures announces further information of its planned IPO on the SWX Swiss Exchange
14.1.2008
HBM BioVentures to apply for listing on the SWX Swiss Exchange